- Conditions
- Metastatic Lung Cancer, Stage IV Lung Cancer
- Interventions
- Stereotactic Body Radiation Therapy, Pembrolizumab
- Radiation · Biological
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Epcoritamab, Gemcitabine, Oxaliplatin, Positron Emission Tomography, Rituximab
- Procedure · Biological · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 3
- States / cities
- Duarte, California • Newnan, Georgia • Zion, Illinois
- Conditions
- Renal Cell Carcinoma
- Interventions
- Total consolidative MPDT
- Procedure
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Oligometastatic Malignant Solid Neoplasm
- Interventions
- Best Practice, Local Consolidation Therapy
- Other · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 12
- States / cities
- Gilbert, Arizona • Little Rock, Arkansas • Honolulu, Hawaii + 8 more
- Conditions
- Muscle Invasive Bladder Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8
- Interventions
- Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Radiosensitizing Agent, Radical Cystectomy, Pelvic Lymphadenectomy, Stereotactic Body Radiation Therapy, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Transurethral Resection of Bladder Tumor, Cystoscopy, Biospecimen Collection, Questionnaire Administration
- Radiation · Drug · Procedure + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Urothelial Carcinoma, Bladder Cancer
- Interventions
- Pembrolizumab, Gemcitabine, Cisplatin, Consolidative Surgery
- Drug · Procedure
- Lead sponsor
- Jason R. Brown
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 9
- States / cities
- Indianapolis, Indiana • St Louis, Missouri • Albuquerque, New Mexico + 3 more
- Conditions
- Lymphoma
- Interventions
- filgrastim, rituximab, sargramostim, carmustine, cisplatin, cyclophosphamide, dexamethasone, etoposide, gemcitabine hydrochloride, melphalan, paclitaxel, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2002
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Non Small Cell Lung Cancer Metastatic
- Interventions
- osimertinib, stereotactic radiosurgery (SRS)
- Drug · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 8
- States / cities
- Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
- Conditions
- Lung Cancer
- Interventions
- Induction Carboplatin, Induction Paclitaxel, Resection, Consolidation Carboplatin, Radiation Therapy, Consolidation Paclitaxel
- Drug · Procedure · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2016
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 17 more
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
- Interventions
- 3-Dimensional Conformal Radiation Therapy (3D-CRT), Docetaxel, Gemcitabine, Intensity-Modulated Radiation Therapy (IMRT), Pemetrexed Disodium, Stereotactic Body Radiation Therapy (SBRT), Erlotinib Hydrochloride, Pembrolizumab
- Radiation · Drug
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 296
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 228 more
- Conditions
- Stage III Lung Cancer AJCC v8, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IIIC Lung Cancer AJCC v8
- Interventions
- Carboplatin, Durvalumab, Gemcitabine, Local Consolidation Therapy, Nab-paclitaxel, Paclitaxel, Pemetrexed, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Locally Advanced Urothelial Carcinoma, Oligo-metastaic Urothelial Carcinoma
- Interventions
- Radical cystectomy
- Procedure
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Rectal Adenocarcinoma
- Interventions
- Chemoradiation, short course radiation therapy, mFOLFOX6, CAPOX, fluoropyrimidine +/- oxaliplatin
- Other · Radiation · Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 99 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
- Interventions
- Clinical Observation, External Beam Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Standard Follow-Up Care, Therapeutic Conventional Surgery
- Other · Radiation · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Houston, Texas
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Squamous Cell Carcinoma of the Esophagus, Stage II Esophageal Cancer, Stage II Gastric Cancer, Stage III Esophageal Cancer, Stage III Gastric Cancer
- Interventions
- erlotinib hydrochloride, oxaliplatin, fluorouracil, radiation therapy, conventional surgery, immunohistochemistry staining method, positron emission tomography, computed tomography, laboratory biomarker analysis, gene expression analysis, fludeoxyglucose F 18
- Drug · Radiation · Procedure + 2 more
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer
- Interventions
- Implantable Microdevice (IMD)
- Combination Product
- Lead sponsor
- Oliver Jonas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Metastatic Sarcoma, Radiation Therapy Patient, Ewing Sarcoma, Rhabdomyosarcoma
- Interventions
- Consolidative radiation therapy (cRT)
- Radiation
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- Up to 39 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland • Minneapolis, Minnesota
- Conditions
- Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, T-Cell Non-Hodgkin Lymphoma
- Interventions
- Anti-Thymocyte Globulin, Cyclosporine, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant, Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells, Total Nodal Irradiation
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Robert Lowsky
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Ipilimumab, Local Consolidation Therapy, Nivolumab, Quality-of-Life Assessment, Radiation Therapy, Therapeutic Conventional Surgery
- Biological · Procedure · Other + 1 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 339 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 5
- States / cities
- Conroe, Texas • Houston, Texas • League City, Texas + 1 more
- Conditions
- Stage IV Non-Small Cell Lung Cancer
- Interventions
- Stereotactic Body Radiation Therapy, Maintenance chemotherapy
- Radiation · Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Metastatic Breast Cancer, HER2-positive Breast Cancer
- Interventions
- Lumpectomy or mastectomy, Radiotherapy, Trastuzumab, Pertuzumab, Paclitaxel, or a combination of these drugs
- Procedure · Radiation · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Prostate Cancer
- Interventions
- Leuprolide Acetate, Bicalutamide, Docetaxel, Prostatectomy, Radiation
- Drug · Procedure · Radiation
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 80 Years · Male only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland
- Conditions
- Leukemia
- Interventions
- therapeutic allogeneic lymphocytes, peripheral blood stem cell transplantation, radiation therapy
- Biological · Procedure · Radiation
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 55 Years to 74 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Seattle, Washington
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- Local consolidative therapy
- Radiation
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania